Current Value
$1.751 Year Return
Current Value
$1.751 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ULST | 0.01% | $637.77M | 0.2% |
AGGH | -0.01% | $309.35M | 0.29% |
TBLL | 0.02% | $2.46B | 0.08% |
MINT | -0.02% | $13.18B | 0.35% |
ICLO | -0.40% | $305.65M | 0.19% |
BILS | 0.59% | $3.96B | 0.1356% |
TBIL | 0.72% | $5.76B | 0.15% |
SPSK | 0.73% | $307.27M | 0.5% |
IVOL | 0.98% | $353.94M | 1.02% |
FTSD | -1.00% | $212.46M | 0.25% |
VRIG | -1.18% | $1.19B | 0.3% |
IBHE | 1.27% | $569.26M | 0.35% |
XONE | 1.48% | $603.24M | 0.03% |
JPLD | 1.56% | $1.19B | 0.24% |
IBTG | 1.57% | $1.88B | 0.07% |
CLOI | 1.75% | $1.07B | 0.4% |
KRBN | 1.78% | $160.09M | 0.85% |
FXE | 1.81% | $525.40M | 0.4% |
CLIP | 2.20% | $1.50B | 0.07% |
CTA | 2.40% | $1.05B | 0.76% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KYMR | 29.96% | $1.95B | -15.67% | 0.00% |
DMRC | 27.63% | $289.87M | -46.16% | 0.00% |
NNOX | 27.29% | $347.50M | -44.56% | 0.00% |
PHR | 26.39% | $1.51B | +6.90% | 0.00% |
AUR | 25.99% | $12.06B | +146.21% | 0.00% |
VNET | 25.97% | $1.58B | +196.53% | 0.00% |
BABA | 25.97% | $296.66B | +44.13% | 0.80% |
ALLT | 25.60% | $319.92M | +268.04% | 0.00% |
QS | 24.45% | $2.38B | -26.68% | 0.00% |
HLX | 24.28% | $1.00B | -43.13% | 0.00% |
RCEL | 24.18% | $158.25M | -19.57% | 0.00% |
AWI | 24.17% | $6.90B | +39.07% | 0.76% |
KGS | 24.17% | $3.13B | +25.86% | 4.71% |
MTRX | 23.97% | $355.62M | +16.56% | 0.00% |
MOS | 23.96% | $11.00B | +12.67% | 2.46% |
DKS | 23.80% | $14.33B | -9.07% | 2.50% |
BLX | 23.72% | $1.49B | +32.52% | 4.04% |
RBBN | 23.63% | $639.09M | +10.70% | 0.00% |
RXO | 23.45% | $2.80B | -19.21% | 0.00% |
AROC | 23.45% | $4.52B | +25.38% | 2.83% |
Yahoo
Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior yearMarch 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior yearMarch 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE
Yahoo
MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will joi
Yahoo
MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com
Yahoo
Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcpDecember 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcpDecember 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024 Quarter AUD$0.7 million up 43% on prior quarter, up 141% on pcpDecember 2024 Half Year AUD$1.1 million up 130% on pcp MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- I
Yahoo
Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce a new
Yahoo
Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDATravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology ResultsTravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome ResponsesTravelan® P2TD (n=866) Uniformed Services University field study randomized 776 subjects MELBOURNE, Australia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharm
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -17.73% | $109.64M | 0.85% |
BTAL | -16.46% | $361.41M | 1.43% |
TAIL | -13.98% | $140.49M | 0.59% |
BIL | -8.97% | $45.95B | 0.1356% |
GBIL | -8.56% | $6.17B | 0.12% |
USDU | -8.40% | $173.44M | 0.5% |
FMF | -6.56% | $153.73M | 0.95% |
XHLF | -6.32% | $1.46B | 0.03% |
SGOV | -5.36% | $45.91B | 0.09% |
KMLM | -5.27% | $188.32M | 0.9% |
TFLO | -5.25% | $7.06B | 0.15% |
TPMN | -4.60% | $31.54M | 0.65% |
UUP | -4.50% | $292.27M | 0.77% |
SOYB | -3.92% | $25.54M | 0.22% |
KCCA | -3.64% | $97.18M | 0.87% |
GOVT | -3.49% | $27.25B | 0.05% |
FXY | -3.24% | $838.61M | 0.4% |
IBTF | -2.82% | $2.12B | 0.07% |
CORN | -2.77% | $49.57M | 0.2% |
VRIG | -1.18% | $1.19B | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ONLN | 28.47% | $75.37M | 0.58% |
IZRL | 27.97% | $105.19M | 0.49% |
JPIE | 26.09% | $3.66B | 0.39% |
EWZ | 25.77% | $4.29B | 0.59% |
IWC | 25.03% | $766.88M | 0.6% |
QQA | 24.53% | $225.66M | 0.29% |
PRNT | 24.24% | $79.83M | 0.66% |
IBUY | 24.05% | $153.59M | 0.65% |
ARGT | 24.02% | $1.16B | 0.59% |
EMQQ | 23.99% | $358.80M | 0.86% |
CWB | 23.94% | $3.79B | 0.4% |
EWZS | 23.86% | $137.30M | 0.6% |
ILF | 23.61% | $1.73B | 0.48% |
GWX | 23.59% | $666.69M | 0.4% |
IFRA | 23.50% | $2.41B | 0.3% |
IWO | 23.48% | $11.36B | 0.24% |
ESPO | 23.27% | $338.45M | 0.56% |
PID | 23.23% | $831.69M | 0.53% |
ICVT | 23.20% | $2.46B | 0.2% |
FLBR | 23.15% | $200.87M | 0.19% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FTAI | -<0.01% | $12.07B | +49.57% | 0.78% |
BJ | -0.05% | $14.71B | +39.60% | 0.00% |
CELH | 0.06% | $10.06B | -57.82% | 0.00% |
WEAV | 0.08% | $813.47M | +18.51% | 0.00% |
SCM | -0.09% | - | - | 11.94% |
TEF | 0.11% | $27.20B | +8.80% | 6.44% |
GOGL | 0.15% | $1.59B | -47.16% | 12.97% |
AIFU | 0.17% | $9.85M | -95.03% | 0.00% |
CYCN | 0.19% | $9.37M | +2.39% | 0.00% |
TLPH | 0.19% | $10.05M | -57.39% | 0.00% |
TDS | 0.22% | $3.93B | +68.38% | 0.46% |
CARV | 0.26% | $7.41M | -22.87% | 0.00% |
IMMP | -0.27% | $289.16M | -32.19% | 0.00% |
RTX | 0.27% | $181.05B | +30.01% | 1.86% |
CXW | 0.27% | $2.39B | +45.07% | 0.00% |
MAT | -0.28% | $6.50B | +7.65% | 0.00% |
PSQH | -0.29% | $89.26M | -49.87% | 0.00% |
AMP | 0.31% | $49.47B | +19.17% | 1.17% |
CHD | -0.31% | $23.29B | -11.36% | 1.23% |
T | -0.32% | $196.66B | +57.98% | 4.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SRRK | -19.82% | $2.92B | +115.29% | 0.00% |
LTM | -15.17% | $11.01B | -96.75% | 2.75% |
CBOE | -10.61% | $22.95B | +20.67% | 1.12% |
RLMD | -9.42% | $13.72M | -88.15% | 0.00% |
K | -9.28% | $28.49B | +32.17% | 2.77% |
MVO | -8.69% | $66.70M | -38.82% | 21.64% |
VSA | -7.77% | $7.04M | -49.24% | 0.00% |
NTIC | -7.30% | $70.11M | -58.10% | 2.97% |
AMED | -7.28% | $3.08B | -1.30% | 0.00% |
ABT | -7.08% | $232.01B | +27.16% | 1.71% |
WBA | -6.60% | $9.67B | -39.04% | 6.69% |
CABO | -6.42% | $926.89M | -58.34% | 7.13% |
ACHV | -6.41% | $94.69M | -46.15% | 0.00% |
OCX | -6.26% | $79.79M | -9.12% | 0.00% |
GORV | -5.81% | $15.42M | -96.17% | 0.00% |
NEUE | -5.54% | $62.05M | +13.56% | 0.00% |
SEG | -5.54% | $239.93M | -26.61% | 0.00% |
DNUT | -5.54% | $548.27M | -73.07% | 4.37% |
MCK | -5.46% | $88.42B | +27.17% | 0.39% |
RMD | -5.41% | $36.45B | +13.01% | 0.85% |